[ad_1]
Trxade Health Inc. (NASDAQ: MEDS), the leading online drug procurement marketplace, is on a mission to provide independent pharmacies with a platform to operate efficiently by digitizing the retail pharmacy experience. Over the years, the company has continued to expand its customer network and expand its core business, while also pursuing strategic partnerships.
The company operates through business segments of Trxade.com, Special Community Pharmacyand Trxade Perdana. Talk to AlphaStreetafter reporting impressive results for the fourth quarter of 2022, Trxade chief executive Suren Ajjarapu provided details on the financial performance in fiscal 2022.
In the management’s decision to sell 100% of the outstanding member’s interest Special Community Pharmacy business, Suren said, “Our core business is B2B, our focus on Community Specialty Pharmacy vs. Community Specialty Pharmacy is really driving new business and we can shift those resources to B2B. I know you may see a drop in revenue in the first two quarters but margins will be high because B2B is a technology business vs Community Specialist Pharmacies have ‘cost of goods sold’ reducing their margins.
He attributed the drop in expenses in recent quarters to cost-cutting strategies and believes the initiative will pay off in a few quarters. When it comes to long-term growth, integration with POS systems will be a key focus this year, in addition to partnerships, according to Suren.
When asked about Trxade’s evolution since last year, Suren said integration is the major change the company has witnessed since last 12 months. According to him, the strong margin growth in fiscal 2022 is the result of the strategy to return to the sale of the core technology platform, which has a gross margin of 78%.
It is worth noting that total gross profit grew by 15% annually in fiscal 2022, helped by a 16% increase in profit to $ 11.4 million. Add double digits on it Tried it and Trxade Perdana parts more than compensate for the weakness Community Specialty Pharmacy division.
The number of users registered on the Trxade Platform increased by 8% in three months, totaling more than 14,400. The company ended the year with total cash of $1.13 million. Full-year net loss decreased to $3.47 million or $0.41 per share from $5.32 million or $0.65 per share in the prior year.
Trxade’s disruptive business model focuses on opening up distribution channels to help pharmacies and patients purchase health products at reasonable prices. The company has successfully brought price transparency to the pharmaceutical market and provided significant savings to its customers. It is on a mission to make healthcare accessible and affordable to millions of patients through innovative solutions.
[ad_2]
Source link